Wednesday, May 8, 2024

Alectinib Approved as an Adjuvant Treatment for Lung Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
05/08/2024
FDA has approved alectinib (Alecensa) as adjuvant therapy for people with lung cancer who have ALK-positive tumors. In a clinical trial, alectinib helped people live longer after surgery without their cancer returning than chemotherapy.

Read the Story - Alectinib Approved as an Adjuvant Treatment for Lung Cancer

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment

Your Weekly Recommended Reads

Powered by AI, personalised for you Catch up on key news and analysis from the week gone by with The Business of Fashion's My...